NSE: IPCALAB | BSE: 524494

Expensive Performer

Download real time

1407.05 4.85 (0.35%)

33.75% Gain from 52W Low

321.7K NSE+BSE Volume

NSE 21 Mar, 2025 3:31 PM (IST)

35,697.4

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Ipca Laboratories Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for IPCALAB, BSE:524494 Ipca Laboratories Ltd.

Search Inside the pdf :

Ipca Laboratories Ltd.

14 Feb 2025

1407.05

0.35%

IPCA LABORATORIES

Accumulate: Ipca Laboratories Ltd.

Prabhudas Lilladhar

Ipca Laboratories Ltd. is trading above its 30 day SMA of 1401.0

Ipca Laboratories Ltd.

27 Dec 2024

1407.05

0.35%

Scaling US operations/outpacing IPM to aid robust earnings growth

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

Following a muted performance in the US over the past eight years due to compliance issues, IPCA is well-poised to revive its US business through new product launches, relaunches, stable pricing in its base business, and the integration of the Unichem business over the next 12-24M.

Ipca Laboratories Ltd. has an average target of 1815.00 from 3 brokers.

Ipca Laboratories Ltd.

18 Nov 2024

1407.05

0.35%

IPCA LABORATORIES

Accumulate: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

Ipca Laboratories Ltd. is trading below its 50 day SMA of 1444.3

Ipca Laboratories Ltd.

14 Nov 2024

1407.05

0.35%

US recovery, Unichem acquisition set to drive growth

Buy: Ipca Laboratories Ltd.

Target

Sharekhan

Quarterly revenues reached Rs. 2,355 crore, marking a 16% y-o-y increase and a 13% rise from the
previous quarter. Profit after tax (PAT) came in strong at Rs. 245 crore, up 39% as compared to last year and 23%, sequentially.

Number of FII/FPI investors increased from 268 to 282 in Dec 2024 qtr.

Ipca Laboratories Ltd.

14 Oct 2024

1407.05

0.35%

At an inflexion point

Buy: Ipca Laboratories Ltd.

Recommendation Target

Motilal Oswal

After three years of earnings deterioration, IPCA is well-poised to deliver strong earnings growth over FY24-27.

Number of FII/FPI investors increased from 268 to 282 in Dec 2024 qtr.

Ipca Laboratories Ltd.

30 Sep 2024

1407.05

0.35%

Bayshore integration to unlock growth

Buy: Ipca Laboratories Ltd.

Target

Sharekhan

Ipca’s board would discuss the strategic integration of Bayshore Pharmaceuticals’ generics business into Unichem Pharma (USA) Inc on September 30, 2024.

Ipca Laboratories Ltd. has an average target of 1815.00 from 3 brokers.

Ipca Laboratories Ltd.

14 Aug 2024

1407.05

0.35%

Strong Q1; UniChem’s turnaround sustainable

Buy: Ipca Laboratories Ltd.

Recommendation Target

Sharekhan

Ipca Laboratories Limited’s (Ipca) earnings came above our estimates, as sales grew 32.9% y-o-y to Rs. 2,092 crore. Sales growth was led by 11.6% y-o-y growth in domestic branded formulations.

Ipca Laboratories Ltd. has an average target of 1815.00 from 3 brokers.

Ipca Laboratories Ltd.

14 Aug 2024

1407.05

0.35%

Domestic formulation drives earnings

Neutral: Ipca Laboratories Ltd.

Target

Motilal Oswal

IPCA delivered better-than-expected 1QFY25 earnings. The improved performance in the domestic formulation (DF) segment was offset to some extent by a subdued show in exports and API segment.